Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots by A. Pece et al.
CASE REPORT Open Access
Intravitreal ranibizumab for choroidal
neovascularization in a patient with angioid
streaks and multiple evanescent white dots
Alfredo Pece1, Davide Allegrini1*, Stelios Kontadakis1, Giuseppe Querques2 and Luca Rossetti3
Abstract
Background: To report a patient with angioid streaks (ASs) and coincident multiple evanescent white dot
syndrome (MEWDS) who developed choroidal neovascularization (CNV).
Case presentation: A 20-year-old woman presented with reduced vision (20/100) in her left eye (LE). Based on a
complete ophthalmologic examination the patient was diagnosed with ASs and coincident MEWDS. Two weeks
later best-corrected visual acuity (BCVA) improved up to 20/25 and the MEWDS findings almost disappeared. Two
months later BCVA dropped again (20/100) due to the development of CNV which was treated by a single
intravitreal injection of ranibizumab (0.5 mg/0.05 mL). One month after this BCVA improved up to 20/40, and there
was regression of the CNV. There was no need for retreatment at the last follow-up visit, 1 year after the
ranibizumab injection, when the patient showed further recovery of BCVA up to 20/25.
Conclusions: In this case of ASs, MEWDS completely resolved after 2 weeks, but 2 months later CNV developed. A
single intravitreal injection of ranibizumab had a long-lasting effect. Larger series are necessary to clarify the
pathogenesis of CNV in such cases and the role of intravitreal ranibizumab.
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Background
Angioid streaks (ASs) are irregular linear breaks in the
Bruch’s membrane that typically taper from the optic
disk, usually associated with various systemic diseases
such as Ehlers-Danlos syndrome, Paget disease, and
pseudoxanthoma elasticum (PXE) [1]. The main vision-
threatening complication of AS is choroidal neovascular-
ization (CNV) which develops in 72–86 % of eyes [2, 3].
Multiple evanescent white dot syndrome (MEWDS) is
a benign inflammatory disorder of unknown etiology
that usually affects young women [4]. >It involves unilat-
eral small, transient white dots at the level of the outer
retina, the retinal pigment epithelium, and the inner
choroid, which have a characteristic appearance on
fluorescein angiography (FA) and indocyanine green
angiography (ICGA). Patients present various symptoms
such as photopsias, blurred vision, sudden decrease in
visual acuity and visual field defects, either temporally or
paracentrally [5]. The prognosis is generally very good,
even though the rare occurrence of CNV may lead to
permanent visual loss [6–10].
Here we report a patient with ASs, diagnosed with co-
incident MEWDS. Two months after the diagnosis of
MEWDS the patient developed CNV, which was effect-
ively treated by intravitreal ranibizumab (Lucentis®,
Novartis, Basel, Switzerland).
Case presentation
A 20-year-old woman with diagnosis of ASs was referred
to our department for reduced vision in her left eye (LE)
of 2 weeks onset; she was negative for pseudoxanthoma
elasticum or any other systemic disease. The patient
signed a comprehensive consent form according to
Good Clinical Practice guidelines, before proceeding
with all examinations and treatments. Her best-
corrected visual acuity (BCVA) was 20/20 in the right
eye (RE) and 20/100 in the LE, with no signs of inflam-
mation in the anterior chamber and vitreous of either
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eye. Fundus biomicroscopy revealed ASs in both eyes
(BE). RE had no evidence of inflammation at the fundus
observation (Fig. 1). Interestingly, only the LE had mul-
tiple discrete grey-white lesions (dots) scattered over
the fundus, from the paramacular area up to the mid-
periphery, and the macula had a granular appearance
(Fig. 2a, b). Fluorescein angiography (FA) (HRA, Heidel-
berg Engineering, Heidelberg, Germany) indicated mild
optic disk leakage with some hyperfluorescent changes
scattered throughout the fundus (paramacular area
and mid-periphery). No CNV was detected (Fig. 2c).
Indocyanine green angiography (ICGA) (HRA, Heidel-
berg Engineering, Heidelberg, Germany) disclosed late
hypofluorescent lesions scattered at the posterior pole
and in the mid-periphery (Fig. 2d); we interpreted
these as signs of zonal outer retinal inflammation.
Spectral-domain optical coherence tomography (SD-OCT)
macular scans showed disruption in the photoreceptor
layer (Fig. 2e). Automated static threshold perimetry indi-
cated visual field defects mainly located paracentrally and
temporally (Fig. 2f).
On the basis of all these findings a diagnosis of ASs
and coincident MEWDS was made. The patient was pre-
scribed oral prednisone (1 mg/kg) for 7 days then half
the dosage for another 7 days.
Two weeks later, LE BCVA improved up to 20/25,
with resolution of the MEWDS findings, except for the
granular appearance at the macula; RE BCVA was 20/20
with no signs of inflammation at the fundus evaluation.
Two months later, the patient returned because of
sudden vision loss in her LE (20/100). FA indicated
CNV in the paramacular area in LE. FA and ICGA
showed no signs of choriocapillaris inflammation in BE
(Fig. 3a, b). We proposed to the patient an intravitreal
Fig. 1 Infrared (IF) (a), Autofluorescence (AF) (b) and fluorescein angiography (FA) (c) images of the right eye (RE) show the angioid streaks (ASs)
with no evidence of inflammation, and choroidal neovascularization (CNV)
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Fig. 2 Fundus color (a) and red-free (b) photographs of the left eye (LE) show multiple discrete grey-white lesions (dots) scattered throughout
the fundus, with a granular appearance in the macula (a and b). Fluorescein angiography (FA) late frame indicates mild optic disk leakage with
some hyperfluorescent changes scattered over the fundus (c). Indocyanine green angiography (ICGA) discloses late hypofluorescent lesions scattered
at the posterior pole and in the mid-periphery (d). Spectral-domain optical coherence tomography (SD-OCT) macular scans show disruption in the
photoreceptor layer (e). Automated static threshold perimetry reveals visual field defects mainly located paracentrally and temporally (f)
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injection of ranibizumab as an off-label treatment op-
tion. She signed informed consent and was given a single
injection of ranibizumab (0.5 mg/0.05 mL) following the
normal procedure. One month after the injection BCVA
improved up to 20/40, the CNV showed regression
(Fig. 3c, d), and there was no need for retreatment up to
her latest follow-up visit 1 year after the injection, when
BCVA had improved up to 20/25.
ASs are often complicated by the appearance of CNV
[2, 3]. To date there are no reports of AS associated with
acute ocular inflammation. MEWDS is a unilateral
inflammatory disease, which usually resolves spontan-
eously, with full recovery [11]. Here we describe a pa-
tient with ASs, who was diagnosed with coincident
MEWDS. Two months after this diagnosis she developed
CNV, which was effectively treated by intravitreal ranibi-
zumab. In the current literature there are only six cases
of CNV that developed after (from 4 weeks to 13 years)
the diagnosis of MEWDS [6–10, 12]. Only two were ef-
fectively treated by intravitreal anti-vascular endothelial
growth factor (VEGF) [10, 12]. In all other cases the vis-
ual loss was permanent despite treatment [6–9].
The case described is unusual: the CNV occurred in a
patient with ASs, 2 months after the diagnosis of
MEWDS. Although both ASs and MEWDS may contrib-
ute to the onset of CNV, the patient’s young age, good
prognosis after intravitreal ranibizumab and the pres-
ence of MEWDS involving the macular area may indi-
cate an inflammatory etiology of the CNV.
Though the pathophysiologic mechanism remains un-
clear, it has been suggested that alterations of Bruch’s
membrane or the outer retinal barrier caused by chor-
oidal inflammation may be associated with ischemic
and/or inflammatory CNV [13]. It has also been hypoth-
esized that the inflammatory processes induce the re-
lease of chemokines that favor angiogenesis [14]. This
patient was in fact younger than the mean age at which
CNV usually develops associated with ASs [15, 16].
Moreover, in this case a single intravitreal ranibizumab
injection had a lasting effect (up to at least 1 year), as
shown by FA and OCT, and by the maintenance of good
BCVA.
Our results are in agreement with Rouvas et al. who
have described the good responses to intravitreal treat-
ment with ranibizumab for inflammatory retinal diseases
[17]. This might be explained by the different nature of
the CNV, in which inflammation may have played an im-
portant pathogenic role, compared to other CNVs sec-
ondary to ASs which tend to be associated with a worse
visual prognosis, and need more injections [15].
Conclusion
In this case of ASs, MEWDS completely resolved after 2
weeks, but 2 months later CNV developed. A single in-
travitreal injection of ranibizumab had a lasting effect.
This illustrates the importance of correct etiological as-
sessment of CNVs, for proper therapeutic management.
Although both ASs and MEWS may have contributed to
Fig. 3 Fluorescein angiography (FA) late frame and spectral-domain optical coherence tomography (SD-OCT) scan showing choroidal neovascularization
(CNV) in the paramacular area 2 months after the diagnosis of multiple evanescent white dot syndrome, corresponding to a zone previously occupied
by outer retinal inflammatory signs (a and b). FA late frame and SD-OCT scan 1 month after intravitreal injection of ranibizumab, showing regression of
the CNV (c and d)
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the CNV in our patient, an inflammatory pathogenesis
must be considered, especially in young patients, where
an idiopathic CNV may be the first manifestation of in-
flammatory chorioretinal diseases [18].
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